OBJECTIVES: This study sought to evaluate myocardial contraction fraction (MCF) as an index of myocardial shortening by comparison to conventional shortening indices in patients with hypertensive hypertrophy, athletes with physiologic hypertrophy and sedentary normal adult subjects. BACKGROUND: A significant percentage of patients with hypertensive hypertrophy have "normal" or "preserved" left ventricular (LV) systolic function by conventional echocardiographic measures whereas their systolic function is depressed when measured by the two-dimensional echocardiographic mid-wall shortening fraction (MWSF). A three-dimensional echocardiographic measure of myocardial shortening analogous to MWSF has been lacking. We describe a volumetric measure of myocardial shortening, the MCF, as the ratio of stroke volume (SV) to myocardial volume (MV), and hypothesize that it may be useful to compare myocardial performance in patients with different degrees and types of hypertrophy. METHODS: We compared the MCF using freehand three-dimensional echocardiographic reconstruction of the LV to conventional measures of LV function (ejection fraction [EF], endocardial shortening fraction [SF] and MWSF) in subjects with pathologic hypertensive hypertrophy, heart failure symptoms and preserved EF (n = 17), athletes with physiologic hypertrophy (n = 41) and normal sedentary adults (n = 80). RESULTS: The EF was in the normal range for all three groups. The MCF was lower in hypertensive hypertrophy compared with normal subjects (0.33 +/- 0.05 vs. 0.44 +/- 0.07, p < 0.01). It also successfully differentiated physiologic hypertrophy from normal subjects (0.50 +/- 0.05 vs. 0.44 +/- 0.07, p < 0.01). The endocardial SF did not distinguish athletes from normal subjects and the MWSF did not distinguish hypertensive from physiologic hypertrophy. CONCLUSIONS: The MCF, a volumetric measure of myocardial shortening, demonstrates that myocardial shortening is decreased in hypertensive hypertrophy and increased in physiologic hypertrophy. The MCF may be useful in assessing differences in myocardial performance in patients with similar degrees of hypertrophy.
OBJECTIVES: This study sought to evaluate myocardial contraction fraction (MCF) as an index of myocardial shortening by comparison to conventional shortening indices in patients with hypertensive hypertrophy, athletes with physiologic hypertrophy and sedentary normal adult subjects. BACKGROUND: A significant percentage of patients with hypertensive hypertrophy have "normal" or "preserved" left ventricular (LV) systolic function by conventional echocardiographic measures whereas their systolic function is depressed when measured by the two-dimensional echocardiographic mid-wall shortening fraction (MWSF). A three-dimensional echocardiographic measure of myocardial shortening analogous to MWSF has been lacking. We describe a volumetric measure of myocardial shortening, the MCF, as the ratio of stroke volume (SV) to myocardial volume (MV), and hypothesize that it may be useful to compare myocardial performance in patients with different degrees and types of hypertrophy. METHODS: We compared the MCF using freehand three-dimensional echocardiographic reconstruction of the LV to conventional measures of LV function (ejection fraction [EF], endocardial shortening fraction [SF] and MWSF) in subjects with pathologic hypertensive hypertrophy, heart failure symptoms and preserved EF (n = 17), athletes with physiologic hypertrophy (n = 41) and normal sedentary adults (n = 80). RESULTS: The EF was in the normal range for all three groups. The MCF was lower in hypertensive hypertrophy compared with normal subjects (0.33 +/- 0.05 vs. 0.44 +/- 0.07, p < 0.01). It also successfully differentiated physiologic hypertrophy from normal subjects (0.50 +/- 0.05 vs. 0.44 +/- 0.07, p < 0.01). The endocardial SF did not distinguish athletes from normal subjects and the MWSF did not distinguish hypertensive from physiologic hypertrophy. CONCLUSIONS: The MCF, a volumetric measure of myocardial shortening, demonstrates that myocardial shortening is decreased in hypertensive hypertrophy and increased in physiologic hypertrophy. The MCF may be useful in assessing differences in myocardial performance in patients with similar degrees of hypertrophy.
Authors: Paolo Milani; Angela Dispenzieri; Christopher G Scott; Morie A Gertz; Stefano Perlini; Roberta Mussinelli; Martha Q Lacy; Francis K Buadi; Shaji Kumar; Mathew S Maurer; Giampaolo Merlini; Suzanne R Hayman; Nelson Leung; David Dingli; Kyle W Klarich; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Patricia A Pellikka; Yi L Hwa; Stephen R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Martha Grogan Journal: Circ Cardiovasc Imaging Date: 2018-05 Impact factor: 7.792
Authors: Mathew S Maurer; William J H Koh; Traci M Bartz; Sirish Vullaganti; Eddy Barasch; Julius M Gardin; John S Gottdiener; Bruce M Psaty; Jorge R Kizer Journal: Am J Cardiol Date: 2016-12-18 Impact factor: 2.778
Authors: Michael L Chuang; Philimon Gona; Carol J Salton; Susan B Yeon; Kraig V Kissinger; Susan J Blease; Daniel Levy; Christopher J O'Donnell; Warren J Manning Journal: Am J Cardiol Date: 2012-02-28 Impact factor: 2.778
Authors: Daisuke Kamimura; Takeki Suzuki; Ervin R Fox; Thomas N Skelton; Michael D Winniford; Michael E Hall Journal: J Card Fail Date: 2017-05-08 Impact factor: 5.712
Authors: Adam Castaño; Albert DeLuca; Richard Weinberg; Ted Pozniakoff; William S Blaner; Altaf Pirmohamed; Brian Bettencourt; Jared Gollob; Verena Karsten; John A Vest; Codruta Chiuzan; Mathew S Maurer; Sabahat Bokhari Journal: J Nucl Cardiol Date: 2015-10-09 Impact factor: 5.952
Authors: Mathew S Maurer; Mazen Hanna; Martha Grogan; Angela Dispenzieri; Ronald Witteles; Brian Drachman; Daniel P Judge; Daniel J Lenihan; Stephen S Gottlieb; Sanjiv J Shah; D Eric Steidley; Hector Ventura; Srinivas Murali; Marc A Silver; Daniel Jacoby; Savitri Fedson; Scott L Hummel; Arnt V Kristen; Thibaud Damy; Violaine Planté-Bordeneuve; Teresa Coelho; Rajiv Mundayat; Ole B Suhr; Márcia Waddington Cruz; Claudio Rapezzi Journal: J Am Coll Cardiol Date: 2016-07-12 Impact factor: 24.094
Authors: Marwah Abdalla; Elvis A Akwo; David A Bluemke; João A C Lima; Daichi Shimbo; Mathew S Maurer; Alain G Bertoni Journal: Int J Cardiol Date: 2019-07-11 Impact factor: 4.164
Authors: Francisco J Romeo; Ignacio M Seropian; Sameer Arora; John P Vavalle; Mariano Falconi; Pablo Oberti; Vadim Kotowicz; Carla R Agatiello; Daniel H Berrocal Journal: Cardiovasc Diagn Ther Date: 2020-02